At the event that was held at the Residence of UK Ambassador “Elsie Inglis House”, 130 guests - representatives of state institutions, the health sector and the non-governmental sector were addressed by HE. Denis Keefe, British Ambassador to Serbia, Sally Storey, VP and Cluster Area Director of GSK for South East Europe, and Marija Krstić, General Manager of GSK for Serbia and Montenegro, presenting GSK’s key pillars and achievements in the previous year in the area of corporate social responsibility (CSR).
Following the panel, guests had the opportunity to visit the patient association fair where the members of different patient groups presented their work in the community though brochures, posters and discussion with the booths visitors. Guests also showed high interest in the Orange Day booth, where GSK employees shared their experience from corporate volunteering initiatives.
- Without a healthy society there is no development and improvement of economic potential - said HM Ambassador to Serbia. He added that GSK operates successfully in Serbia when it comes to improving people's health, but also that it is a responsible company that supports numerous projects and initiatives that are beneficial to the entire community.
Talking about GSK’s values, Sally Storey said:
- As a science-led global healthcare company, we have a strong commitment to operating responsibly while addressing some of society’s biggest healthcare challenges. And whilst we are being recognized for what we do practically to help - last year, we ranked first in the Access to Medicine Index for the fifth consecutive time and we also topped Fortune’s Change the World list - this independent external recognition comes not just as result of what we do, but also how we do it – said Storey.
Marija Krstić stressed that GSK’s priority is to improve the access to innovative medicines for patients in Serbia.
- Thanks to our tiered pricing approach to prescription medicines, GSK’s innovative therapies for the treatment of HIV and respiratory diseases have recently been included in the reimbursement list in Serbia, giving HCPs and patients new options to treat and manage their diseases - added Krstić.
She emphasized that one of the company’s main CSR pillar is ethical behavior. GSK is leading the industry when it comes to patient-centric interaction with HCPs and transparency. Transparency standards that GSK applies are the highest in the industry and are far stricter than those prescribed by European and national legislation, in order to increase patient trust by helping to remove any perceived conflict of interest between GSK and prescribers and therefore meet the evolving expectations of society.
Ms Krstić added that wider than its access to innovative products, GSK is also committed to strengthening the healthcare system and improving health and well-being in the community through financial resources, product donations and employee volunteering, as well as through the driving disease prevention programs.